Literature DB >> 2958547

Preparation and performance of bispecific F(ab' gamma)2 antibody containing thioether-linked Fab' gamma fragments.

M J Glennie1, H M McBride, A T Worth, G T Stevenson.   

Abstract

A simple and efficient method is described for the production of pure bispecific F(ab' gamma)2 heterodimers, in which the individual antibody Fab' gamma fragments are joined via a stable thioether linkage. Hybrid molecules were constructed from both mouse monoclonal and rabbit polyclonal antibodies with equal efficiency, in the combinations mouse-rabbit and mouse-mouse. Peptic F(ab' gamma)2 fragments from the two chosen antibodies were first reduced to provide Fab' gamma SH. The SH groups on one of the Fab' gamma SH partners were then fully alkylated with o-phenylenedi-maleimide to provide free maleimide groups. Finally the two preparations, Fab' gamma mal and Fab' gamma SH, combined under conditions which allowed cross-linking of the maleimide and SH groups and avoided reoxidation of SH groups. The major product isolated from the reaction mixture after chromatography was always the F(ab' gamma)2 heterodimer (50 to 70%), other products being unreacted Fab' gamma and trace amounts of putative F(ab' gamma)3. Immunochemical analysis revealed that the thioether-linked F(ab' gamma)2 molecules were essentially all heterodimers, most of which had been joined via their Fd chains. The dual specificity of F(ab' gamma)2 heterodimers was tested functionally in three systems: 1) the combination (anti-idiotype + anti-phycoerythrin) linked L2C cells to the fluorochrome phycoerythrin, allowing fluorescence analysis; 2) the combination (anti-idiotype + anti-saporin) linked L2C cells to the ribosome-inactivating protein saporin, and transformed a subtoxic dose of saporin into a highly toxic mixture which prevented further protein synthesis by L2C cells; and 3) the combination of anti-idiotype with 3G8 (antibody to the Fc gamma receptor CD16) subjected L2C cells to cytotoxic attack by human mononuclear effectors.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2958547

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  41 in total

1.  Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity.

Authors:  Jianying Dong; Arlene Sereno; William B Snyder; Brian R Miller; Susan Tamraz; Adam Doern; Michael Favis; Xiufeng Wu; Hon Tran; Emma Langley; Ingrid Joseph; Antonio Boccia; Rebecca Kelly; Kathleen Wortham; Qin Wang; Lisa Berquist; Flora Huang; Sharon X Gao; Ying Zhang; Alexey Lugovskoy; Shelly Martin; Heather Gouvis; Steven Berkowitz; Gisela Chiang; Mitchell Reff; Scott M Glaser; Kandasamy Hariharan; Stephen J Demarest
Journal:  J Biol Chem       Date:  2010-12-01       Impact factor: 5.157

Review 2.  Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on.

Authors:  Gert Riethmüller
Journal:  Cancer Immun       Date:  2012-05-01

Review 3.  Are BiTEs the "missing link" in cancer therapy?

Authors:  Carter M Suryadevara; Patrick C Gedeon; Luis Sanchez-Perez; Terence Verla; Christopher Alvarez-Breckenridge; Bryan D Choi; Peter E Fecci; John H Sampson
Journal:  Oncoimmunology       Date:  2015-04-30       Impact factor: 8.110

4.  Mammalian expression of single chain variable region fragments dimerized by Fc regions.

Authors:  T Kato; K Sato; S Suzuki; H Sasakawa; M Kurokawa; K Nishioka; K Yamamoto
Journal:  Mol Biol Rep       Date:  1995       Impact factor: 2.316

Review 5.  Bispecific antibody: a tool for diagnosis and treatment of disease.

Authors:  S Songsivilai; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

6.  Activatory and inhibitory Fcγ receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain.

Authors:  Andrew T Vaughan; Claude H T Chan; Christian Klein; Martin J Glennie; Stephen A Beers; Mark S Cragg
Journal:  J Biol Chem       Date:  2015-01-07       Impact factor: 5.157

7.  Preparation and analysis of bifunctional immunoconjugates containing monoclonal antibodies OKT3 and BABR1.

Authors:  P D Foglesong; M A Winkler; J O Price; G D Marshall; S H Reagh; D A Bush; K S Hixson; W H West
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

8.  bisFabs: Tools for rapidly screening hybridoma IgGs for their activities as bispecific antibodies.

Authors:  Sanket Patke; Ji Li; Peiyin Wang; Dion Slaga; Jennifer Johnston; Sunil Bhakta; Siler Panowski; Liping L Sun; Teemu Junttila; Justin M Scheer; Diego A Ellerman
Journal:  MAbs       Date:  2017-01-26       Impact factor: 5.857

Review 9.  Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.

Authors:  William R Strohl; Michael Naso
Journal:  Antibodies (Basel)       Date:  2019-07-03

10.  Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells.

Authors:  Andrei Ivanov; Stephen A Beers; Claire A Walshe; Jamie Honeychurch; Waleed Alduaij; Kerry L Cox; Kathleen N Potter; Stephen Murray; Claude H T Chan; Tetyana Klymenko; Jekaterina Erenpreisa; Martin J Glennie; Tim M Illidge; Mark S Cragg
Journal:  J Clin Invest       Date:  2009-07-20       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.